Topic: central nervous system
Biohaven’s new formulation of ALS drug riluzole has helped people with social anxiety face the challenge of speaking in public.
Karuna will start mid-stage trials of a Lilly drug, shelved due to side effects, as part of a combination therapy for schizophrenia later this year.
A startup exited stealth mode to push a new class of drugs that could help regenerate nerve cells’ insulating myelin sheaths in diseases such as MS.
Alzheon is still trying to build a case for a pivotal trial of its Alzheimer’s candidate and says new data support its plans.
Orion Pharma is pressing ahead with a pivotal trial for its amyotrophic lateral sclerosis drug ODM-109, despite mixed results in a phase 2 trial.
Titan gets the OK to start stage two in a trial of its ropinirole implant for Parkinson’s—but has to postpone because of financial constraints.
Johnson & Johnson unit Janssen joins the Alzheimer's failure club after deciding to stop trials of its BACE inhibitor atabacestat.
EIP Pharma is enrolling a phase 2b trial of neflamapimod, which targets synaptic dysfunction.
Alnylam is gearing up to move RNAi therapies for central nervous system disorders into the clinic.
Johnson & Johnson looks increasingly like it is onto a winner with esketamine for resistant depression—though one phase 3 trial missed the mark.